• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

  • Twitter
  • YouTube
NASBS

NASBS

North American Skull Base Society

  • Home
  • About
    • Mission Statement
    • Bylaws
    • NASBS Board of Directors
    • Committees
      • Committee Interest Form
    • NASBS Policy
    • Donate Now to the NASBS
    • Contact Us
  • Industry
    • Exhibits and Support & Visibility Opportunities
    • Industry Archives
  • Meetings
    • 2026 Annual Meeting
    • Abstracts
      • 2026 Call for Abstracts
      • NASBS Poster Archives
      • 2025 Abstract Awards
    • 2025 Recap
    • NASBS Summer Course
    • Meetings Archive
    • Other Skull Base Surgery Educational Events
  • Resources
    • Member Survey Application
    • NASBS Travel Scholarship Program
    • Research Grants
    • Fellowship Registry
    • The Rhoton Collection
    • Webinars
      • Research Committee Workshop Series
      • ARS/AHNS/NASBS Sinonasal Webinar
      • Surgeon’s Log
      • Advancing Scholarship Series
      • Trials During Turnover: Webinar Series
    • NASBS iCare Pathway Resources
    • Billing & Coding White Paper
  • Membership
    • Join NASBS
    • Membership Directory
    • Multidisciplinary Teams of Distinction
    • NASBS Mentorship Program
  • Fellowship Match
    • NASBS Neurosurgery Skull Base Fellowship Match Programs
    • NASBS Neurosurgery Skull Base Fellowship Match Application
  • Journal
  • Login/Logout

2025 Proffered Presentations

2025 Proffered Presentations

 

← Back to Previous Page

 

S070: LONG TERM OUTCOME OF CENTRAL NEUROCYTOMA: A MULTICENTER STUDY OF ELEVN TERTIARY CARE CENTERS
Balgees Ajlan, MD; Dalhousie University

Background: Central neurocytoma is a rare primarily intraventricular tumor that affects young adults. It’s a WHO grade 2 tumor and complete surgical resection is often curative. Due to its peculiar location, gross total resection is often challenging, and adjuvant radiotherapy is sometimes indicated. Factors associated with outcome are not well addressed in the literature.

Methods: A multicenter retrospective cohort study was conducted among 13 tertiary care centers in Saudi Arabia. All eligible patients with a histologically confirmed central neurocytoma between the years of 2000-2022 were included. Modified Rankin Scale (mRS) ≤2 was considered as a favourable outcome while >2 as unfavorable.

Results: A total of 104 patients were included with a mean age of 26± 10.43 years. Majority (85.6%) presented with headache. Pre-operative mRS was 0-2 in 93% of the cases. Mean tumor size was 48 mm (SD 12-91 mm). transcortical approach was used in 62%, transcallosal in 35.2% and trans-sulcal in 2.8%. Gross total resection (GTR) was achieved in 50.7%. Radiotherapy was needed in 40% and Ventriculoperitoneal shunt in 38.6%. The mean duration of follow up was 62 months. favorable outcome was observed in 81.7%. The mRs score improved in 31.7%. regressed in 26% and was unchanged in 42.3%. Factors associated with worse outcome included initial mRs of ≥3, tumor size ≥50 mm, and atypical anaplastic histology. Disease progression was observed in 18 (17.8%). Five-year absolute survival rates 91.55%. The only significant predictor of disease progression was the presence of atypical features or anaplasia (P .007). Extent of surgical resection (P 0.877) wasn’t associated with disease progression. Post operative radiotherapy didn’t alter residual progression in patients with subtotal resection (P .170) nor the recurrence rate in those with gross total resection (.365)

Conclusion: Central Neurocytoma cases have a high survival rate with a favourable mRs score at long-term follow up. The extent of surgical resection didn’t alter disease progression nor did the adjuvant radiotherapy.  

 

← Back to Previous Page

Copyright © 2025 North American Skull Base Society · Managed by BSC Management, Inc · All Rights Reserved